METTL1

Across TCGA pan-cancer cohorts, METTL1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated METTL1 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher METTL1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated METTL1 expression acts as an unfavorable survival marker, although some lineages such as COAD and GBM show a favorable association.

CCRCC, COAD, and PDAC are the cancer types where METTL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.439	0.897	<.001	53	view →
COAD	DFS	Median	All	1.000	0.887	.021	24	view →
PDAC	OS	Median	II,III,IV	0.443	0.596	.016	5	view →
GBM	OS	Median	All	0.478	0.294	.024	4	view →
LSCC	OS	Median	III,IV	0.751	0.956	.017	4	view →
LUAD	DFS	Tertile	II,III,IV	0.956	0.660	.025	4	view →
HNSC	DFS	Quartile	III,IV	0.891	1.000	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

METTL1–CCRCC (DFS)

Open the CCRCC breakdown →